More News! For those who want to keep up with everything

destiny pharma mrsa antibiotic resistance

More News! 29 Jan 2019

Antibiotic Nasal Gel for Surgical Infections Cruises Through Phase I

An antibiotic nasal gel, developed by the UK company Destiny Pharma to treat drug-resistant bacterial infections, has shown no adverse effects in healthy volunteers in a phase I trial. Destiny’s antibiotic nasal gel is designed to prevent post-surgical infections of the bacterial species Staphylococcus aureus, which can come in the dangerous drug-resistant strain MRSA. “About […]

January 29, 2019 - 3 minutesmins - By Jonathan Smith

exxonMobil biofuel renewable energy group clariant

More News! 24 Jan 2019

ExxonMobil Recruits Swiss Company to Make Biofuels

The Swiss biofuels company Clariant is joining up with US companies ExxonMobil and the Renewable Energy Group to make biodiesel from agricultural waste. The new partnership hopes to combine technology from the Renewable Energy Group and Clariant to produce biodiesel — a biofuel that is a mix of ethanol and fat or cooking greases. Unlike […]

January 24, 2019 - 2 minutesmins - By Jonathan Smith

More News! 21 Jan 2019

Danish Biotech Turns Bacteria into Fermentation Workaholics

The Danish biotech Enduro Genetics has shown it can improve the yield of fermentation by engineering bacteria to become ‘addicted’ to being productive. Fermentation vats full of bacteria or yeast are the workhorses for industries such as the pharmaceutical and chemical industry. They are used to mass-produce products including detergents, drugs and biofuels. The cells […]

January 21, 2019 - 3 minutesmins - By Jonathan Smith

More News! 14 Jan 2019

Inhaled Lung Disease Treatment Encounters Mixed Results in Phase II Trial

An inhaled drug from British company Verona Pharma has failed to significantly improve lung function in patients with the lung disease chronic obstructive pulmonary disease, though it did produce some benefits. The 79 patients in the phase II trial suffered from chronic obstructive pulmonary disease, a condition where inflammation in the lungs restricts the airways […]

January 14, 2019 - 3 minutesmins - By Jonathan Smith

Morphogen IX pulmonary arterial hypertension

More News! 20 Dec 2018

Cambridge Company Raises €20M for Potential First in Lung Disease

Morphogen-IX, based in Cambridge, has raised €20.4M (£18.4M) to fund a new type of treatments for pulmonary arterial hypertension. The Series B financing will go towards the preclinical development of the company’s lead candidate, which has the potential to become the first to treat the condition rather than just addressing the symptoms. People with pulmonary […]

December 20, 2018 - 1 minutemin - By Clara Rodríguez Fernández

More News! 14 Dec 2018

Cultured Meat Company Offers a Taste of the First Lab-Grown Steak

The Israeli company Aleph Farms has shared with the world the first prototype of a beef steak that has been grown in a lab, harming no animal in the process. Although the world’s first lab-grown burger was tasted in 2013, growing a steak had so far remained a challenge. “We are the first company that […]

December 14, 2018 - 3 minutesmins - By Clara Rodríguez Fernández

genomics machine learning personalized medicine

More News! 10 Dec 2018

British Company Raises €37M to Personalize Therapies with Machine Learning

Genomics, a company based in Oxford, has increased the amount raised in a Series B round that will fund further development of its genomics technology for personalized medicine. The company adds a further €9M (£8M) to the round with the participation of Foresite Capital and F-Prime Capital, two renowned US life sciences investors. The previous […]

December 10, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

cambridge nature placenta organoid stemcell fetus

More News! 29 Nov 2018

Long-Lasting Placenta Organoids Could Improve Pregnancy Research

Researchers have made 3D placenta organoids from human cells that can last for over a year, improving over the current models to study disease in pregnancy and develop drugs. Researchers at the University of Cambridge grew the organoids from stem cells extracted from donated placenta tissue at 6-9 weeks of pregnancy. The organoids replicated the […]

November 29, 2018 - 2 minutesmins - By Jonathan Smith

More News! 22 Nov 2018

First Drug for Rare Inflammation Syndrome Approved by FDA

The FDA has approved the first drug for the treatment of a rare condition in which the body produces too many active immune cells, developed in a Swiss-Swedish partnership. The antibody drug, emapalumab, is approved to treat primary hemophagocytic lymphohistiocytosis. This condition is a rare, often fatal syndrome in which the immune system produces too […]

November 22, 2018 - 2 minutesmins - By Jonathan Smith

More News! 20 Nov 2018

Phase I Gives Hope for First Zika Vaccine

Results from a Phase I trial showed promising safety and efficacy of a potential first vaccine against the mosquito-borne Zika virus, developed by French biotech Valneva and US biopharma Emergent BioSolutions. In the US-based Phase I trial, 67 participants were injected with either placebo or inactivated forms of the virus as a vaccine. Two months later, […]

November 20, 2018 - 2 minutesmins - By Jonathan Smith

Inflazome Forbion inflammatory disease macrophage

More News! 19 Nov 2018

Anti-Inflammatory Treatments Get €40M Boost in Series B

A Series B funding round has whipped up €40M for the Irish company Inflazome. This money will help to fund clinical trials for anti-inflammatory treatments targeting conditions such as Alzheimer’s and Parkinson’s disease. “We are extremely excited about this opportunity, which is such a large funding round in a European company,” Marco Boorsma, General Partner […]

November 19, 2018 - 2 minutesmins - By Jonathan Smith

mission therapeutics abbvie parkinsons disease

More News! 16 Nov 2018

AbbVie Enters Industry Collaboration to Fight Alzheimer’s and Parkinson’s Disease

The UK biotech Mission Therapeutics has teamed up with AbbVie to develop new drugs to treat the neurodegenerative conditions Alzheimer’s disease and Parkinson’s disease. The new collaboration aims to fund the preclinical development of drugs that inhibit proteins called deubiquitinating enzymes. Deubiquitinating enzymes modify proteins in the cell, controlling essential functions such as what the […]

November 16, 2018 - 2 minutesmins - By Jonathan Smith

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us